Syncona Share Discussion Threads

[alan@bj] 16/1/2019 16:37

Why the drop today?

[brexitplus] 14/1/2019 16:12

Autolus Therapeutics Enters Lease with Alexandria Real Estate Equities, Inc. for Future Commercial-Scale Manufacturing Site and U.S. Headquarters

Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. (NYSE: ARE) for the construction and development of an 85,000 square foot build-to-suit facility to be located in the Shady Grove Life Sciences Center in Rockville, Maryland. The new facility will house offices for Autolus’ U.S.-based research and development, commercial and corporate functions and serve as its first full commercial-scale manufacturing center, with a planned capacity to produce 5,000 T cell therapies annually. In addition, Autolus has established a temporary U.S. headquarters in Rockville until the new facility is ready for occupancy, which is currently expected to occur in 2021.

[ltinvestor] 06/1/2019 22:26

Ian Cowie in today’s Sunday Times has highlighted Syncona and bought shares at 266p....

[luxaeterna1] 24/12/2018 13:49

Yes, I also see occasional mentions of Axumin for breast cancer, although this seems a couple of years away from hitting the clinical trial pathway, will be interesting to watch.

[brexitplus] 13/12/2018 09:34

Just a bit more about potential from Blue Earth website

“Fluciclovine F 18 is an artificial amino acid that has been labelled with F 18 to allow positron emission tomography (PET) imaging. Fluciclovine F 18 appears to be avidly taken up by a number of cancer cell types, including prostate cancer and glioma (a type of brain tumour).

Blue Earth Diagnostics is investigating fluciclovine F 18 as a molecular diagnostic imaging agent for various cancers. It has been evaluated most extensively for disease localisation and detection in prostate cancer patients with suspected biochemical recurrence following earlier treatment.

Prostate Cancer

Blue Earth Diagnostics’ first product, Axumin™ (fluciclovine F 18), was approved by the U.S. Food & Drug Administration (FDA) in May 2016 for use in PET imaging of biochemically recurrent prostate cancer. In May 2017, the European Medicines Agency (EMA) granted marketing authorisation for Axumin use in PET imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment.

Blue Earth Diagnostics filed for marketing approval for Axumin with both the FDA and the EMA based on studies conducted on over 800 subjects in the USA, Italy and Norway.

In May 2018, Blue Earth Diagnostics expanded its prostate cancer portfolio through the acquisition of exclusive, worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer. rhPSMA is a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer.

Glioma

Blue Earth Diagnostics has obtained Orphan Drug Designation (ODD) from the FDA and the EMA for the use of fluciclovine F 18 in the diagnosis of glioma, a form of brain cancer. Gliomas make up about 30% of all brain and central nervous system tumours and 80% of all malignant brain tumours. The symptoms, prognosis, and treatment of a malignant glioma depend on the person’s age, the exact type of tumour, and the location of the tumour – which often penetrates deep into the brain. Blue Earth Diagnostics plans to investigate the role of fluciclovine F 18 PET imaging in evaluating the spread of both high and low grade glioma within the brains of affected patients.

Other diseases

The company anticipates the development of follow-on indications for fluciclovine 18 in the diagnosis of other tumour types, as well as other applications in prostate cancer.

[ltinvestor] 12/12/2018 19:39

Axumin( Blue Earth) now available in France

[brexitplus] 12/12/2018 11:25

Lux

Yes, more great news today. I’ve contacted Syncona to ask if they will be issuing their usual RNSs about the two releases.

It appears the Blue Earth news, according to Syncona, only justifies going out via their email to investors. So sign up today!!!

[luxaeterna1] 12/12/2018 11:15

Blue Earth on a roll by the sounds of it

hxxp://www.blueearthdiagnostics.com/first-production-and-administration-of-axumin-fluciclovine-18f-in-france/

First patients commercially dosed in France (for prostate).

Update: "Axumin is commercially available in France, Norway, the Czech Republic, The Netherlands, United Kingdom and Austria with further European countries set to follow soon."

[brexitplus] 12/12/2018 07:01

This is new news, following publication of test results on 19th November.

Well spotted. I’m surprised Syncona didn’t release an RNS.

[luxaeterna1] 11/12/2018 14:05

hxxps://www.synconaltd.com/investors/news/blue-earth-diagnostics-announces-us-food-and-drug-administration-fda-filing-acceptance-of-supplemental-new-drug-application-snda-for-18f-fluciclovine-pet-imaging-in-glioma/?accept_disclaimer=true

it appears that Blue Earth have sent Axumin phase 3 trial data to the FDA for a second condition, ie cancerous brain gliomas. I am not 100% clear if this is major news or just ongoing pr.

[brexitplus] 06/12/2018 16:35

Autolus doing well despite the US falls.

[rambutan2] 21/11/2018 18:18

Results presentation:



and webcast available here:

[ltinvestor] 21/11/2018 08:28

Syncona also made charitable donations of £4.7m during the last year.This, IMO, is an exceptional company...

[brexitplus] 21/11/2018 08:15

I wouldn’t be surprised if there is a lot of outside interest in Blue Earth. User numbers increasing quickly. Large newsflow in the past few months. Profitable.

[davidlloyd] 21/11/2018 08:01

Very good numbers!
Happy days.
DL

[ltinvestor] 21/11/2018 07:32

As I said over a year ago when the share price was around £1.70.Buy,sit back and watch the growth....Blue Earth diagnostics very undervalued in the accounts...

[brexitplus] 21/11/2018 07:28

Excellent interims.

[brexitplus] 19/11/2018 14:59

Autolus share price all over the place recently but looks like an upward trend. Nightstar a bit variable.

[brexitplus] 13/11/2018 07:25

Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company, Nightstar Therapeutics Plc (NASDAQ: NITE) (Nightstar), has announced the initiation of its Phase 2/3 Expansion Study in XIRIUS Trial for NSR-RPGR in XLRP and has reported Third Quarter 2018 Financial Results.



The announcement can be accessed on Nightstar's investor website at hxxp://ir.nightstartx.com

[ltinvestor] 10/11/2018 16:21

Nightstar up $2.5 in 3 days and presenting this coming week in London and two weeks later in New York.Presently $12.5 and wouldn’t be surprised to see $18 by end Dec

[brexitplus] 10/11/2018 06:27

Autolus finished at $48 last night with a high of $53.

[luxaeterna1] 09/11/2018 09:24

Autolus spike ~30% last night in the US - News? New investor?

[ltinvestor] 09/11/2018 08:01

Bought Nightstar at $10....raised $80m a few weeks ago at $18!!

[luxaeterna1] 07/11/2018 16:59

Yes...there are 15 types of cancers targeted on page 10.